Join the Gastric Cancer group to help and get support from people like you.
Gastric Cancer News
Four-Gene Combo Might Predict Lethality Of Stomach Cancer
FRIDAY, April 25, 2025 — Four specific genes serve as a telltale clue to how potentially deadly stomach cancers will develop and progress, a new study says. Testing for these genetic mutations could e...
Guidelines Developed for Management of Gastric Premalignant Conditions
TUESDAY, March 25, 2025 – In a clinical guideline issued by the American College of Gastroenterology and published online March 12 in the American Journal of Gastroenterology, recommendations are ...
FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1)
On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the...
Black Cancer Death Rate Declining, But Higher Risk Remains
FRIDAY, Feb. 21, 2025 – Cancer deaths among Black men and women in the U.S. have declined during the past decade in the United States, a new American Cancer Society (ACS) report says. The cancer...
Gastric Cancer Is a Considerable Health Concern Worldwide
MONDAY, Jan. 13, 2025 – Gastric cancer (GC) is a considerable health concern worldwide, especially among men and in East Asia, according to a study recently published in Cancer Biology & Medicine....
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
FRIDAY, Jan. 3, 2025 – The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid...
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...
Tevimbra Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
SAN MATEO, Calif.--(BUSINESS WIRE)-- December 27, 2024 – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd.,...
FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction Cancer
WEDNESDAY, Oct. 23, 2024 – The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line...
FDA Approves Vyloy (zolbetuximab-clzb) for the Treatment of Advanced Gastric and GEJ Cancer
TOKYO, Oct. 18, 2024 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved...
Study Quantifies Risk for Gastric, Breast Cancer for Germline CDH1 P/LP Variants
FRIDAY, June 21, 2024 – The cumulative risk for advanced gastric cancer varies from 6.5 to 10.3 percent for carriers of germline CDH1 pathogenic/likely pathogenic (P/LP) variants, according to a...
Gastrectomy for Gastric Cancer Tied to Lower Risk for Cardiovascular Events
TUESDAY, June 4, 2024 – Patients with gastric cancer who undergo gastrectomy have a lower risk for cardiovascular events than the general population, according to a study published online March 28...
Oral Rinse Might Alert Doctors to Stomach Cancers
FRIDAY, May 10, 2024 – A quick swish at the doctor’s office could someday provide early detection of stomach cancer, the fourth-leading cause of cancer deaths worldwide, a new study reports. R...
FDA Approves Hercessi (trastuzumab-strf), a Biosimilar to Herceptin
DURHAM, N.C., April 29, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...
FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status
PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial ...